A potentially severe acute respiratory infection caused by the novel coronavirus severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2).[1] The clinical presentation is generally that of a respiratory infection
with a symptom severity ranging from a mild common cold-like illness, to a severe viral ...
Betacoronavirus/pathogenicity,
Coronavirus Infections/diagnostic imaging,
Coronavirus Infections/complications,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/diagnostic imaging,
Pneumonia, Viral/drug therapy,
Pneumonia, Viral/complications,
Pandemics/statistics & numerical data,
Symptom Flare Up,
Risk Groups,
China/epidemiology,
Healthcare-Associated Pneumonia/diagnosis,
Health Personnel/organization & administration,
Carrier State/transmission,
Infectious Disease Transmission, Vertical/prevention & control
The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID‑19 pandemic. This includes people presenting to hospital with moderate to severe community-acquired pneumonia and people who develop pneumonia w...
Betacoronavirus,
Pneumonia, Viral/complications,
Coronavirus Infections/complications,
Antibiotics, Antitubercular/therapeutic use,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/drug therapy,
Hospitals/standards,
Coronavirus Infections/diagnosis,
Pneumonia, Viral/diagnosis
China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discussesthe guidelines related to COVID-19 in China in order to provide important references for other countries
...
Betacoronavirus/drug effects,
Pneumonia, Viral/epidemiology,
Coronavirus Infections/epidemiology,
China/epidemiology,
Pandemics/prevention & control,
Pandemics/statistics & numerical data,
Epidemiological Monitoring,
Health Information Management/methods,
Interferons/therapeutic use,
Lopinavir/therapeutic use,
Ritonavir/therapeutic use,
Ribavirin/therapeutic use,
Chloroquine/therapeutic use,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/drug therapy
Bhimraj, Adarsh;
Morgan, Rebecca L;
Shumaker, Amy Hirsch;
Lavergne, Valery;
Baden, Lindsey;
Cheng, Vincent Chi-Chung;
Edwards, Kathryn M;
Gandhi, Rajesh;
Muller, William J;
O’Horo, John C;
Shoham, Shmuel;
Murad, M. Hassan;
Mustafa, Reem A;
Sultan, Shahnaz;
Falck-Ytter, Yngve.
Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19....
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice....
This guideline aims to provide specific, patient-focused recommendations on management and care of people with suspected or confirmed COVID-19. With the exception of chemoprophylaxis for the prevention of infection in people exposed to COVID-19, the guideline does not include other interventions used in ...
Clinical Diagnosis/diagnosis,
Betacoronavirus/drug effects,
Coronavirus Infections/diagnosis,
Pneumonia, Viral/diagnosis,
Hypoxia/diagnosis,
Patient Acuity,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/drug therapy,
Dexamethasone/therapeutic use,
Breast Feeding,
Antiviral Agents/therapeutic use,
Hydroxychloroquine/therapeutic use,
Colchicine/therapeutic use,
Plasma/immunology,
Darunavir/therapeutic use,
Interferons/therapeutic use,
Evidence-Based Practice/methods